Homing and survivability of genetically modified mononuclear umbilical cord blood cells after transplantation into transgenic G93A mice with amyotrophic lateral sclerosis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To overcome the effects of neurodegeneration, as an alternative option of pharmacotherapy, the genetically modified human umbilical cord blood mononuclear cells overexpressing vascular endothelial growth factor (VEGF), glial-derived neurotrophic factor (GDNF), neuronal cell adhesion molecule (NCAM) were suggested. The migration potential and survivability of the genetically modified cells based on expression of therapeutic gene in different combinations after transplantation into G93A mice with amyotrophic lateral sclerosis model was studied The pattern of homing and survivability of the genetically modified cells in a spinal chord after different period of time after treatment was shown by immunofluorescent analysis Based on the level of survived cells and the combination of therapeutic genes the life extension of G93A mice was observed.

Full Text

Restricted Access

About the authors

Z. Z Safiullov

Kazan State Medical University

E. E Garanina

Kazan (Volga region) Federal University

A. A Izmailov

Kazan State Medical University

R. R Garifulin

Kazan State Medical University

V. Y Fedotova

Kazan (Volga region) Federal University

I. I Salafutdinov

Kazan (Volga region) Federal University

A. A Rizvanov

Kazan (Volga region) Federal University

R. R Islamov

Kazan State Medical University

References

  1. Federici T., Boulis M.N. Gene therapy for amyotrophic lateral sclerosis. Neurobiol. Dis. 2012; 48(2): 236-6.
  2. Taha M.F. Cell based-gene delivery approaches for the treatment of spinal cord injury and neurodegenerative disorders Curr Stem Cell Ther. 2010; 5(1): 23-13.
  3. Garbuzova-Davis S., Rodrigues M.C., Mirtyl S. et al. Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS. PLoS One 2012; 7(2): e31254.
  4. Chen J., Bernreuther C., Dihne M. et al. Celladhesion molecule l1-transfected embryonic stem cells with enhanced survival support regrowth of corticospinal tract axons in mice after spinal cord injury Neurotrauma 2005; 22(8): 896-10.
  5. Krakova D., Mulcrone P., Meyer M. et al. Synergistic effects of GDNF and VEGF on lifespan and disease progression in familial ALS rat model. Mol. Ther. 2013; 21(8): 1602-8.
  6. Федотова, Е.Е. Черенкова, Р.Р. Исламов и др. Создание рекомбинантных аденовирусов, кодирующих гены нейральных мо лекул клеточной адгезии ncam1, ncam2 и l1cam. Клеточная трансплантология и тканевая инженерия 2013; 8(3): 142-6.
  7. Черенкова Е.Е., Федотова В.Ю., Борисов М.А. и др. Создание рекомбинантных аденовирусов и лентивирусов, экспрессирующих ангиогенные и нейропротекторные факторы, с помощью технологии клонирования Gateway Клеточная трансплантология и тканевая инженерия 2012; 7(3): 164-8.
  8. Islamov R.R., Rizvanov A.A., Mukhamedyarov M.A. et al. Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis mouse model after transplantation of human umbilical cord blood cells genetically modified with adenoviral vectors expressing a neuroprotective factor and a neural cell adhesion molecule. Curr. Gene Ther. 2015; 15(3): 266-10.
  9. Rizvanov A.A., Kiyasov A.P., Gazizov I.M. et al. Human umbilical cord blood cells transfected with VEGF and L(1)CAM do not differentiate into neurons but transform into vascular endothelial cell and secrete neuro-trophic factors to support neuro-genesis-a novel approach in stem cell therapy. Neurochem. Int. 2008; 53(6-8): 389-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies